As Cytokinetics Inc. moved closer to its first drug approval, and investors sent its stock price higher, CEO Robert Blum last year reaped the rewards. Blum, who helped launch the South San ...

In a regulatory filing, Cytokinetics (CYTK) president and CEO Robert Blum disclosed the sale of 15,000 common shares of the company on March 31 at a price of $40.75 per share. Discover the latest ...

Cytokinetics, Incorporated has a fifty-two week low of $40.53 and a fifty-two week high of $75.71. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics' chief executive Robert Blum said on a conference call that the therapy had a "substantial effect" in the study compared to placebo in obstructive HCM, and seemed to be effective ...

Robert Blum. The likelihood now is that Cytokinetics will have to re-align itself around aficamten, currently in the SEQUOIA-HCM pivotal trial which is due to generate results later in 2023 ...

Cytokinetics was a surefire takeover candidate — until it wasn't. Please watch the video at Investors.com - Biotech Stocks Are Shooting Higher. Here's How You Can Play Them. On May 22 ...

But the biotech stock has since pulled back almost 44% from that point. Cytokinetics Chief Executive Robert Blum called the results of the Sequoia study "pristine." "The consistency and the ...

March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq ... Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive ...

It’s my pleasure to introduce our presenting next presenting company Cytokinetics. On the stage with me, we have Robert Blum, President and Chief Executive Officer. We also have Andrew Callas, EVP, ...

Robert I. Blum, Cytokinetics' President and CEO, stated, "With regulatory submissions on file in the U.S., Europe and China for aficamten and regulatory review activities underway, we are ...

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global ...